Jawad Haider Butt1, Jonas Bjerring Olesen2, Anna Gundlund2, Thomas Kümler3, Peter Skov Olsen4, Eva Havers-Borgersen1, David Thein Aagaard1, Gunnar Hilmar Gislason2,5,6, Christian Torp-Pedersen7, Lars Køber1, Emil Loldrup Fosbøl1. 1. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 2. Department of Cardiology, Herlev and Gentofte University Hospital, Hellerup, Denmark. 3. Department of Cardiology, Herlev and Gentofte University Hospital, Herlev, Denmark. 4. Department of Cardiothoracic Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 5. The Danish Heart Foundation, Copenhagen, Denmark. 6. The National Institute of Public Health, University of Southern Denmark, Odense, Denmark. 7. Department of Cardiology, Nordsjællands Hospital, Hillerød, Denmark.
Abstract
Importance: New-onset postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery. However, data on the long-term risk of thromboembolism in patients who develop POAF after heart valve surgery are conflicting. In addition, data on stroke prophylaxis in this setting are lacking. Objective: To assess the long-term risk of thromboembolism in patients developing new-onset POAF after isolated left-sided heart valve surgery relative to patients with nonsurgical, nonvalvular atrial fibrillation (NVAF). Design, Setting, and Participants: This observational cohort study was conducted from January 1, 2000, through December 31, 2015, using Danish nationwide registries and the Eastern Danish Heart Surgery Database. Patients who developed POAF after isolated left-sided heart valve surgery (bioprosthetic aortic or mitral valve replacement and/or aortic or mitral valve repair) from 2000 through 2015 were included. These patients were matched with patients with nonsurgical NVAF in a 1:3 ratio by age, sex, heart failure, hypertension, diabetes, a history of thromboembolism, ischemic heart disease, and year of diagnosis. Data analyses took place from January to March 2019. Main Outcomes and Measures: Rates of thromboembolism. Results: Of the 1587 patients who underwent isolated left-sided heart valve surgery, 741 patients (46.7%) developed POAF during admission. Of the 712 patients with POAF who were eligible for matching, 675 patients were matched with 2025 patients with NVAF and made up the study population. In the matched study population, the median age was 71 (interquartile range, 65-77) years, and 1600 (59.3%) were men. Oral anticoagulation therapy was initiated within 30 days postdischarge in 420 patients with POAF (62.9%) and in 1030 patients with NVAF (51.4%). The crude incidence rates of thromboembolism were 21.9 (95% CI, 17.4-27.6) and 17.7 (95% CI, 15.2-20.6) events per 1000 person-years for patients with POAF and patients with NVAF, respectively. In the adjusted analysis, the long-term risk of thromboembolism was similar in patients with POAF and NVAF (hazard ratio, 1.22 [95% CI, 0.88-1.68]). Oral anticoagulation therapy during follow-up was associated with a lower risk of thromboembolic events in patients with POAF (hazard ratio, 0.45 [95% CI, 0.22-0.90]) as well as patients with NVAF (hazard ratio, 0.63 [95% CI, 0.45-0.87]) compared with no anticoagulation therapy. Conclusions and Relevance: New-onset POAF after isolated left-sided heart valve surgery was associated with a similar long-term risk of thromboembolism as NVAF. These data warrant studies addressing the role of anticoagulation therapy in POAF after left-sided heart valve surgery.
Importance: New-onset postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery. However, data on the long-term risk of thromboembolism in patients who develop POAF after heart valve surgery are conflicting. In addition, data on stroke prophylaxis in this setting are lacking. Objective: To assess the long-term risk of thromboembolism in patients developing new-onset POAF after isolated left-sided heart valve surgery relative to patients with nonsurgical, nonvalvular atrial fibrillation (NVAF). Design, Setting, and Participants: This observational cohort study was conducted from January 1, 2000, through December 31, 2015, using Danish nationwide registries and the Eastern Danish Heart Surgery Database. Patients who developed POAF after isolated left-sided heart valve surgery (bioprosthetic aortic or mitral valve replacement and/or aortic or mitral valve repair) from 2000 through 2015 were included. These patients were matched with patients with nonsurgical NVAF in a 1:3 ratio by age, sex, heart failure, hypertension, diabetes, a history of thromboembolism, ischemic heart disease, and year of diagnosis. Data analyses took place from January to March 2019. Main Outcomes and Measures: Rates of thromboembolism. Results: Of the 1587 patients who underwent isolated left-sided heart valve surgery, 741 patients (46.7%) developed POAF during admission. Of the 712 patients with POAF who were eligible for matching, 675 patients were matched with 2025 patients with NVAF and made up the study population. In the matched study population, the median age was 71 (interquartile range, 65-77) years, and 1600 (59.3%) were men. Oral anticoagulation therapy was initiated within 30 days postdischarge in 420 patients with POAF (62.9%) and in 1030 patients with NVAF (51.4%). The crude incidence rates of thromboembolism were 21.9 (95% CI, 17.4-27.6) and 17.7 (95% CI, 15.2-20.6) events per 1000 person-years for patients with POAF and patients with NVAF, respectively. In the adjusted analysis, the long-term risk of thromboembolism was similar in patients with POAF and NVAF (hazard ratio, 1.22 [95% CI, 0.88-1.68]). Oral anticoagulation therapy during follow-up was associated with a lower risk of thromboembolic events in patients with POAF (hazard ratio, 0.45 [95% CI, 0.22-0.90]) as well as patients with NVAF (hazard ratio, 0.63 [95% CI, 0.45-0.87]) compared with no anticoagulation therapy. Conclusions and Relevance: New-onset POAF after isolated left-sided heart valve surgery was associated with a similar long-term risk of thromboembolism as NVAF. These data warrant studies addressing the role of anticoagulation therapy in POAF after left-sided heart valve surgery.
Authors: Michela Brambatti; Stuart J Connolly; Michael R Gold; Carlos A Morillo; Alessandro Capucci; Carmine Muto; Chu P Lau; Isabelle C Van Gelder; Stefan H Hohnloser; Mark Carlson; Eric Fain; Juliet Nakamya; Georges H Mairesse; Marta Halytska; Wei Q Deng; Carsten W Israel; Jeff S Healey Journal: Circulation Date: 2014-03-14 Impact factor: 29.690
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld Journal: Eur J Cardiothorac Surg Date: 2016-09-23 Impact factor: 4.191
Authors: Benjamin A Steinberg; Yue Zhao; Xia He; Adrian F Hernandez; David A Fullerton; Kevin L Thomas; Roger Mills; Winslow Klaskala; Eric D Peterson; Jonathan P Piccini Journal: Clin Cardiol Date: 2013-12-18 Impact factor: 2.882
Authors: Thomas Andersen Rix; Sam Riahi; Kim Overvad; Søren Lundbye-Christensen; Erik Berg Schmidt; Albert Marni Joensen Journal: Scand Cardiovasc J Date: 2012-03-29 Impact factor: 1.589
Authors: Spencer J Melby; James F George; Desiree J Picone; Jerald Payden Wallace; James E Davies; David J George; James K Kirklin Journal: J Thorac Cardiovasc Surg Date: 2014-11-21 Impact factor: 5.209
Authors: Steven J Kernis; Vuyisile T Nkomo; David Messika-Zeitoun; Bernard J Gersh; Thoralf M Sundt; Karla V Ballman; Christopher G Scott; Hartzell V Schaff; Maurice Enriquez-Sarano Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: Jonas Bjerring Olesen; Gregory Y H Lip; Morten Lock Hansen; Peter Riis Hansen; Janne Schurmann Tolstrup; Jesper Lindhardsen; Christian Selmer; Ole Ahlehoff; Anne-Marie Schjerning Olsen; Gunnar Hilmar Gislason; Christian Torp-Pedersen Journal: BMJ Date: 2011-01-31
Authors: Nicole Lowres; Graham S Hillis; Marc A Gladman; Mark Kol; Jim Rogers; Vincent Chow; Ferris Touma; Cara Barnes; Joanne Auston; Ben Freedman Journal: Int J Cardiol Heart Vasc Date: 2020-06-29
Authors: Michael K Wang; Pascal B Meyre; Rachel Heo; P J Devereaux; Lauren Birchenough; Richard Whitlock; William F McIntyre; Yu Chiao Peter Chen; Muhammad Zain Ali; Fausto Biancari; Jawad Haider Butt; Jeff S Healey; Emilie P Belley-Côté; Andre Lamy; David Conen Journal: CJC Open Date: 2021-09-16
Authors: Michael Ke Wang; Rachel Heo; Pascal Meyre; Louis Park; Steffen Blum; William F McIntyre; Emilie Belley-Côté; Lauren Birchenough; Kiven Vuong; Jeff S Healey; P J Devereaux; André Lamy; David Conen Journal: CJC Open Date: 2022-06-10